CAR-T and cellular gene therapies are too expensive

Boro Dropulić

DOI: https://doi.org/10.1038/s41591-024-03231-z

IF: 82.9

2024-09-05

Nature Medicine

Abstract:Point-of-care manufacturing and technology transfer can deliver cellular gene therapies at an affordable cost to patients across the world.

biochemistry & molecular biology,cell biology,medicine, research & experimental

What problem does this paper attempt to address?

Technological and Manufacturing Innovation Drive Improved Access to Engineered T Cell Therapies

Ying Xiong,Yanping Xie,Zhongyu Zhu,Ibeawuchi Oparaocha,Oxana Sleesareva,Boro Dropulić,Rimas Orentas

DOI: https://doi.org/10.18103/mra.v11i11.4759

2023-01-01

Medical Research Archives

Abstract:The creation of autologous gene-modified cell products, such as CAR-T cells (chimeric antigen receptor T cells) has met with clinical success but has been severely restricted by cost, availability, and current commercial models of central manufacturing. Moreover, the inability to produce CAR-T cells at reasonable cost in all but the largest centers slow innovation. CAR-T cells are unique in that these ex vivo expanded effector T cell populations express activation receptors comprised of immunoglobulin-like binders, or other immune ligands, bypassing the restriction of expanding and appropriately activating effector cells that arise by recombination of V-D-J genetic elements. However, the use of a single binding moiety to recognize leukemia target cells has selected for the generation of escape mutants, or for cryptic clones to expand that were not initially detected upon diagnostic work-up. To meet this challenge, we have engineered both B cell malignancy-specific and HIV surface antigen-specific CAR-T cells that express multiple binding moieties, thereby reducing the chance of immune escape. The creation of a therapeutic CAR-T cell population also requires a complex set of procedures that includes procurement of a large number of patient T cells, most often by leukapheresis, activation of the T cell population using matrix-associated antibodies targeting the T cell receptor and an immune co-receptor, a gene vector to permanently transduce T cells, and a bioreactor that can accommodate the expansion of the engineered cell population to numbers suitable for infusion. This complex set of procedures, combined with the current central processing model, has led to a complex chain of custody and expensive temperature-controlled shipping requirements. We present here a model whereby production of CAR-T cells at the point of care, using simplified cell procurement, purification, and expansion, can reduce the time and expense of CAR-T cell generation, with the aim to expand the use of these therapies in both the majority world, and in managed care or publicly funded systems. The CAR-T populations produced in this point-of-care ready process are highly active, viable, and have preferred CAR-T phenotypic characteristics associated with clinical efficacy.
Challenges in Global Access to CAR-T Cells: an Asian Perspective.

William Yk Hwang,Satoshi Takahashi,Bryan Choi,He Huang,Shin Kawamata,Soo Chin Ng,Pawan Gupta,Amir Ali Hamidieh,Chaiyong Koaykul,Cospiahadi Irawan,Alok Srivastava

DOI: https://doi.org/10.31547/bct-2023-023

2023-01-01

Abstract:The use of cell therapy for clinical applications has seen a dramatic increase in recent years, primarily in oncology, especially with the use of chimeric antigen receptor (CAR) T-cell therapies. However, there are some barriers to the widespread adoption of CAR-T cell therapies globally, primarily because of the high cost of manufacturing these cells and clinical infrastructure considerations. We reviewed the different strategies adopted across Asia to implement CAR-T cell therapy and found that these included patient assistance programs, close engagement with funders, cost-effectiveness studies, on-site manufacturing of CAR-T cells, and joint ventures between local partners and foreign pharmaceutical companies. Although on-site manufacturing can reduce the cost of genetic engineering and expansion, it does not address many other hidden costs and quality considerations. Future growth in large-scale regional manufacturing, facilitated by cutting-edge science and innovation, could reduce costs through economies of scale and facilitate the eagerly needed global access.
Manufacturing innovation to drive down cell therapy costs

Minsoo Khang,Smruthi Suryaprakash,Megan Kotrappa,Widya Mulyasasmita,Shana Topp,John Wu

DOI: https://doi.org/10.1016/j.tibtech.2023.04.006

Abstract:Chimeric antigen receptor T cells (CAR-T) have demonstrated their potential to revolutionize cancer treatment. However, manufacturing remains a challenge. Multiple manufacturing innovations [e.g., vector and gene engineering, process improvements, hardware innovation, digital innovation, and point-of-care (POC) manufacturing] have the potential to help realize the full potential of CAR-T therapies.
CAR T-Cell Production Using Nonviral Approaches

Viktor Lukjanov,Irena Koutná,Pavel Šimara

DOI: https://doi.org/10.1155/2021/6644685

2021-03-27

Abstract:Chimeric antigen receptor T-cells (CAR T-cells) represent a novel and promising approach in cancer immunotherapy. According to the World Health Organization (WHO), the number of oncological patients is steadily growing in developed countries despite immense progress in oncological treatments, and the prognosis of individual patients is still relatively poor. Exceptional results have been recorded for CAR T-cell therapy in patients suffering from B-cell malignancies. This success opens up the possibility of using the same approach for other types of cancers. To date, the most common method for CAR T-cell generation is the use of viral vectors. However, dealing with virus-derived vectors brings possible obstacles in the CAR T-cell manufacturing process owing to strict regulations and high cost demands. Alternative approaches may facilitate further development and the transfer of the method to clinical practice. The most promising substitutes for virus-derived vectors are transposon-derived vectors, most commonly sleeping beauty, which offer great coding capability and a safe integration profile while maintaining a relatively low production cost. This review is aimed at summarizing the state of the art of nonviral approaches in CAR T-cell generation, with a unique perspective on the conditions in clinical applications and current Good Manufacturing Practice. If CAR T-cell therapy is to be routinely used in medical practice, the manufacturing cost and complexity need to be as low as possible, and transposon-based vectors seem to meet these criteria better than viral-based vectors.
CAR-T cell therapy in India requires a paradigm shift in training, education and health care processes

Akshay Ravindranath,Aparajita Dubey,Surekha Suresh,Guljit Chaudhuri,Narendra Chirmule

DOI: https://doi.org/10.1016/j.jcyt.2021.09.007

IF: 6.196

Cytotherapy

Abstract:Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of some kinds of cancers. Hundreds of companies and academic institutions are collaborating to develop gene-modified cell therapies using novel targets, different cell types, and manufacturing processes of autologous and allogenic cell therapies. The individualized, custom-made autologous CAR-T cell production platform remains a significant limiting factor for its large-scale clinical application. In this respect, the advances in standardization and automation of the process can have considerable impact on cost reduction. Development of off-the-shelf, ready-to-use universal killer cells can enable scaling up. Despite the wide use of this cell therapy in the United States, Europe and China, its development is limited in developing countries in Southeast Asia, Africa and Latin America. In this review, we focus on good manufacturing practices-compliant manufacturing requirements, operational logistics, and regulatory processes that need to be considered for high-quality gene-modified cell therapies from an Indian perspective. We also list the potential strategies to overcome challenges associated with translation to affordability and scalability.
Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health

Véronique Raimond,Emmanuelle Kaltenbach,Christophe Adam,Sébastien Lazzarotto,Catherine Le Galès,Lionel Perrier,Jérôme Wittwer

DOI: https://doi.org/10.1016/j.bulcan.2021.09.001

Abstract:Since 2013, the process of pricing of innovative drugs by the French National Health Insurance has considered both cost-effectiveness and budget impact. CAR-T cell therapies were first subject to economic evaluation from 2019 in France. We aim to describe the process and results of the economic evaluation of tisagenlecleucel and axicabtagene ciloleucel as well as the challenges these evaluations raised. Evaluations submitted by the firms were reviewed by HAS and submitted to the Committee of Economic Evaluation and Public Health (CEESP). The CEESP issued opinions related to: (1) the methodological quality of economic evidence and, (2) the cost-effectiveness and budget impact of the drugs. The CEESP invalidated the estimated incremental cost-utility ratios (ICUR) of tisagenlecleucel due to the insufficient clinical evidence and methodological quality to extrapolate the long-term progression of the disease after treatment and compare tisagenlecleucel with alternatives. The CEESP concluded that tisagenlecleucel was not proven cost-effective. The estimated ICUR of axicabtagene ciloleucel at €114,509/QALY vs. chemotherapies was associated with an acceptable level of methodological quality despite being based on a weak indirect comparison and limited data on quality of life. The CEESP considered axicabtagene ciloleucel ICUR to be "very high" and questioned the societal/community willingness-to-pay of the claimed price. The primary source of uncertainty surrounding the ICUR estimates of both drugs was the lack of hindsight on effectiveness. The economic evaluation of CAR-T cell therapies highlights the risk of inefficient resource allocation driven by limited clinical data. It calls for payment schemes accounting for this risk and effective collection of post-marketing data.
Lentiviral Vectors in CAR-T Cell Manufacturing: Biological Principles, Manufacturing Process, and Frontier Development

Ge Yang

DOI: https://doi.org/10.54097/5qz2zr53

2023-12-29

Abstract:Chimeric antigen receptor T cell (CAR-T) therapy, as the preeminent strategy in immunotherapy, has conferred benefits upon numerous cancer patients. Currently, there are six CAR-T therapies approved by the Food and Drug Administration (FDA), while the China National Medical Products Administration (NMPA) has approved three. The manufacturing process for CAR-T cells (CAR-Ts) entails using lentiviral vectors (LVVs), which are efficacious in transducing functional genes to both dividing and nondividing cells. Also, LVVs exert their capacity to integrate relatively large segments of DNA. Despite this fact, LVV-based CAR-Ts production can prove prohibitively expensive, and the yield of LVV can be further enhanced. In recent years, in-vivo generation of CAR-Ts has attracted significant attention since it stands to eliminate the ex-vivo isolation and activation process for T cells, thereby decreasing the cost and time involved in production. In view of this, this review summarizes the biological principles of LVVs and their manufacturing process, which encompasses lentiviral vector production, T cell isolation and activation, and CAR-Ts production. Additionally, the cutting-edge developments associated with LVVs are outlined herein, offering direction for the production of the next generation of CAR-Ts.
Availability and financing of CAR-T cell therapies: A cross-country comparative analysis

Yulia Litvinova,Sherry Merkur,Sara Allin,Ester Angulo-Pueyo,Daiga Behmane,Enrique Bernal-Delgado,Miriam Dalmas,Antonio De Belvis,Nigel Edwards,Francisco Estupiñán-Romero,Peter Gaal,Sophie Gerkens,Margaret Jamieson,Alisha Morsella,Dario Picecchi,Hilde Røshol,Ingrid Sperre Saunes,Terry Sullivan,Balázs Szécsényi-Nagy,Inneke Van De Vijver,Ricciardi Walter,Dimitra Panteli

DOI: https://doi.org/10.1016/j.healthpol.2024.105153

IF: 3.255

Health Policy

Abstract:Chimeric antigen receptor T-cell therapies (CAR-T therapies) are a type of advanced therapy medicinal product (ATMP) that belong to a new generation of personalised cancer immunotherapies. This paper compares the approval, availability and financing of CAR-T cell therapies in ten countries. It also examines the implementation of this type of ATMP within the health care system, describing the organizational elements of CAR-T therapy delivery and the challenges of ensuring equitable access to all those in need, taking a more systems-oriented view. It finds that the availability of CAR-T therapies varies across countries, reflecting the heterogeneity in the organization and financing of specialised care, particularly oncology care. Countries have been cautious in designing reimbursement models for CAR-T cell therapies, establishing limited managed entry arrangements under public payers, either based on outcomes or as an evidence development scheme to allow for the study of real-world therapeutic efficacy. The delivery model of CAR-T therapies is concentrated around existing experienced cancer centres and highlights the need for high networking and referral capacity. Some countries have transparent and systematic eligibility criteria to help ensure more equitable access to therapies. Overall, as with other pharmaceuticals, there is limited transparency in pricing, eligibility criteria and budgeting decisions in this therapeutic area.
Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative

Jon Rueda,Íñigo de Miguel Beriain,Lluis Montoliu

DOI: https://doi.org/10.1089/crispr.2024.0042

Abstract:Casgevy, the world's first approved CRISPR-based cell therapy, has been priced at $2.2 million per patient. Although this hefty price tag was widely anticipated, the extremely high cost of this and other cell and gene therapies poses a major ethical issue in terms of equitable access and global health. In this Perspective, we argue that lowering the prices of future CRISPR therapies is an urgent ethical imperative. Although we focus on Casgevy as a case study, much of our analysis can be extrapolated to the controversies over affordable access to other gene and cell therapies. First, we explain why this first-of-its-kind CRISPR therapy might be so expensive. We then analyze the ethical issues of equity and global health of early CRISPR treatments. Next, we discuss potential solutions to lower the prices of CRISPR gene therapies. We conclude that the approval of CRISPR transforms our obligations of justice and compels us to bring future gene therapies to the maximum possible number of patients with serious genetic diseases at affordable prices.
Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?

Caroline Lonez,Eytan Breman

DOI: https://doi.org/10.3390/cells13020146

IF: 6

2024-01-13

Cells

Abstract:This last decade, chimeric antigen receptor (CAR) T-cell therapy has become a real treatment option for patients with B-cell malignancies, while multiple efforts are being made to extend this therapy to other malignancies and broader patient populations. However, several limitations remain, including those associated with the time-consuming and highly personalized manufacturing of autologous CAR-Ts. Technologies to establish "off-the-shelf" allogeneic CAR-Ts with low alloreactivity are currently being developed, with a strong focus on gene-editing technologies. Although these technologies have many advantages, they have also strong limitations, including double-strand breaks in the DNA with multiple associated safety risks as well as the lack of modulation. As an alternative, non-gene-editing technologies provide an interesting approach to support the development of allogeneic CAR-Ts in the future, with possibilities of fine-tuning gene expression and easy development. Here, we will review the different ways allogeneic CAR-Ts can be manufactured and discuss which technologies are currently used. The biggest hurdles for successful therapy of allogeneic CAR-Ts will be summarized, and finally, an overview of the current clinical evidence for allogeneic CAR-Ts in comparison to its autologous counterpart will be given.

cell biology
Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility

Lorenzo Giorgioni,Alessandra Ambrosone,Maria Francesca Cometa,Anna Laura Salvati,Robert Nisticò,Armando Magrelli

DOI: https://doi.org/10.3390/ijms251910365

IF: 5.6

2024-09-27

International Journal of Molecular Sciences

Abstract:Chimeric antigen receptor (CAR) T-cell therapy has achieved notable success in treating hematological cancers but faces significant challenges in solid-tumor treatment and overall efficacy. Key limitations include T-cell exhaustion, tumor relapse, immunosuppressive tumor microenvironments (TME), immunogenicity, and antigen heterogeneity. To address these issues, various genetic engineering strategies have been proposed. Approaches such as overexpression of transcription factors or metabolic armoring and dynamic CAR regulation are being explored to improve CAR T-cell function and safety. Other efforts to improve CAR T-cell efficacy in solid tumors include targeting novel antigens or developing alternative strategies to address antigen diversity. Despite the promising preclinical results of these solutions, challenges remain in translating CAR T-cell therapies to the clinic to enable economically viable access to these transformative medicines. The efficiency and scalability of autologous CAR T-cell therapy production are hindered by traditional, manual processes which are costly, time-consuming, and prone to variability and contamination. These high-cost, time-intensive processes have complex quality-control requirements. Recent advancements suggest that smaller, decentralized solutions such as microbioreactors and automated point-of-care systems could improve production efficiency, reduce costs, and shorten manufacturing timelines, especially when coupled with innovative manufacturing methods such as transposons and lipid nanoparticles. Future advancements may include harmonized consumables and AI-enabled technologies, which promise to streamline manufacturing, reduce costs, and enhance production quality.

biochemistry & molecular biology,chemistry, multidisciplinary
A roadmap for affordable genetic medicines

Melinda Kliegman,Manar Zaghlula,Susan Abrahamson,Jonathan H. Esensten,Ross Wilson,Fyodor D. Urnov,Jennifer A. Doudna

DOI: https://doi.org/10.1038/s41586-024-07800-7

IF: 64.8

2024-07-18

Nature

Abstract:Nineteen genetic therapies have been approved by the U.S. Food and Drug Administration (FDA) to date, a number that now includes the first CRISPR genome editing therapy for sickle cell disease, CASGEVY (exagamglogene autotemcel). This extraordinary milestone is widely celebrated because of the promise for future genome editing treatments of previously intractable genetic disorders and cancers. At the same time, such genetic therapies are the most expensive drugs on the market, with list prices exceeding $4 million per patient. Although all approved cell and gene therapies trace their origins to academic or government research institutions, reliance on for-profit pharmaceutical companies for subsequent development and commercialization results in prices that prioritize recouping investments, paying for candidate product failures, and meeting investor and shareholder expectations. To increase affordability and access, sustainable discovery-to-market alternatives are needed that address system-wide deficiencies. Here, we present recommendations of a multi-disciplinary task force assembled to chart such a path. We describe a pricing structure that, once implemented, could reduce per-patient cost tenfold and propose a business model that distributes responsibilities while leveraging diverse funding sources. We also outline how academic licensing provisions, manufacturing innovation and supportive regulations can reduce cost and enable broader patient treatment.

multidisciplinary sciences
Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma

Frederick W Thielen,Renaud J S D Heine,Sibren van den Berg,Renske M T Ten Ham,Carin A Uyl-de Groot

DOI: https://doi.org/10.1016/j.jcyt.2022.09.002

IF: 6.196

Cytotherapy

Abstract:Background aims: Drug prices are regarded as one of the most influential factors in determining accessibility and affordability to novel therapies. Cell and gene therapies such as OTL-200 (brand name: Libmeldy) and AVXS-101 (brand name: Zolgensma) with (expected) list prices of 3.0 million EUR and 1.9 million EUR per treatment, respectively, spark a global debate on the affordability of such therapies. The aim of this study was to use a recently published cost-based pricing model to calculate prices for cell and gene therapies, with OTL-200 and AVXS-101 as case study examples. Methods: Using the pricing model proposed by Uyl-de Groot and Löwenberg, we estimated a price for both therapies. We searched the literature and online public sources to estimate (i) research and development (R&D) expenses adjusted for risk of failure and cost of capital, (ii) the eligible patient population and (iii) costs of drug manufacturing to calculate a base-case price for OTL-200 and AVXS-101. All model input parameters were varied in a stepwise, deterministic sensitivity analysis and scenario analyses to assess their impact on the calculated prices. Results: Prices for OTL-200 and AVXS-101 were estimated at 1 048 138 EUR and 380 444 EUR per treatment, respectively. In deterministic sensitivity analyses, varying R&D estimates had the greatest impact on the price for OTL-200, whereas for AVXS-101, changes in the profit margin changed the calculated price substantially. Highest prices in scenario analyses were achieved when assuming the lowest number of patients for OTL-200 and highest R&D expenses for AVXS-101. The lowest R&D expenses scenario resulted in lowest prices for either therapy. Conclusions: Our results show that, using the proposed model, prices for both OTL-200 and AVXS-101 lie substantially below the currently (proposed) list prices for both therapies. Nevertheless, the uncertainty of the used model input parameters is considerable, which translates in a wide range of estimated prices. This is mainly because of a lack of transparency from pharmaceutical companies regarding R&D expenses and the costs of drug manufacturing. Simultaneously, the disease indications for both therapies remain heavily understudied in terms of their epidemiological profile. Despite the considerable variation in the estimated prices, our results may support the public debate on value-based and cost-based pricing models, and on "fair" drug prices in general.
Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India

Hamenth Kumar Palani,Arun Kumar Arunachalam,Mohammed Yasar,Arvind Venkatraman,Uday Kulkarni,Sharon Anbumalar Lionel,Sushil Selvarajan,Anu Korula,Aby Abraham,Biju George,Jennifer E Adair,Rimas Orentas,Boro Dropulic,Vikram Mathews

DOI: https://doi.org/10.1038/s41409-022-01866-5

Abstract:Chimeric Antigen Receptor (CAR) T cell therapy is an accepted standard of care for relapsed/refractory B cell malignancies. However, the high cost of existing industry-driven centralized production makes this therapy unaffordable in low and middle-income countries. Decentralized or point of care manufacturing has the potential to overcome some of these challenges. Here we demonstrate a decentralized manufacturing process for anti-CD19-CAR-T cells using a fully automated closed system (Miltenyi CliniMACS Prodigy®) is feasible in a developing country setting. Validation run data, as part of a pre-clinical trial safety evaluation, demonstrates the successful and robust manufacturing of anti-CD19 CAR-T cells with T cell expansion of 25 to 47-fold. The median transduction efficiency was 48.8%, with a median viability of 98% and fulfillment of all standard release criteria assays for clinical application. Evaluation of production costs in an academic, not for profit setting in India provide a benchmark for low and middle-income pricing which could greatly increase access to this therapy. Based on our analysis, the cost per product would be approximately $35,107 US dollars. Our data highlights the safety, efficacy, and reproducibility of the process for use in planned future clinical trials.
Reducing the costs of blockbuster gene and cell therapies in the Global South

Ben Johnson

DOI: https://doi.org/10.1038/s41587-023-02049-3

IF: 46.9

2024-01-12

Nature Biotechnology

Abstract:Researchers in low- and middle-income countries are developing their own IP, scaling up local manufacturing, and looking for biomarkers — all in the hope of bringing costs down and getting therapies to people who need them.

biotechnology & applied microbiology
Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review

Vahid Moradi,Elnaz Khodabandehloo,Mehdi Alidadi,Azadeh Omidkhoda,Naser Ahmadbeigi

DOI: https://doi.org/10.3389/fonc.2024.1388475

IF: 4.7

2024-06-08

Frontiers in Oncology

Abstract:CAR-T cell therapy has shown remarkable promise in treating B-cell malignancies, which has sparked optimism about its potential to treat other types of cancer as well. Nevertheless, the Expectations of CAR-T cell therapy in solid tumors and non-B cell hematologic malignancies have not been met. Furthermore, safety concerns regarding the use of viral vectors and the current personalized production process are other bottlenecks that limit its widespread use. In recent years the use of gene editing technology in CAR-T cell therapy has opened a new way to unleash the latent potentials of CAR-T cell therapy and lessen its associated challenges. Moreover, gene editing tools have paved the way to manufacturing CAR-T cells in a fully non-viral approach as well as providing a universal, off-the-shelf product. Despite all the advantages of gene editing strategies, the off-target activity of classical gene editing tools (ZFNs, TALENs, and CRISPR/Cas9) remains a major concern. Accordingly, several efforts have been made in recent years to reduce their off-target activity and genotoxicity, leading to the introduction of advanced gene editing tools with an improved safety profile. In this review, we begin by examining advanced gene editing tools, providing an overview of how these technologies are currently being applied in clinical trials of CAR-T cell therapies. Following this, we explore various gene editing strategies aimed at enhancing the safety and efficacy of CAR-T cell therapy.

oncology
Importance of CAR-T cell therapy monitoring using high-throughput assays

Matt Alexander,Chelsea B. Pratt

DOI: https://doi.org/10.1016/j.drudis.2022.06.010

IF: 8.369

2022-06-28

Drug Discovery Today

Abstract:Advances in the development of chimeric antigen receptor (CAR)-T cells have undermined the paramount importance of this technology for the success of adoptive T-cell immunotherapy. The bespoke production of autologous CAR-T cells is a lengthy and costly process. Thus, the development of more cost-effective allogeneic 'off-the-shelf' CAR-T cells provides a more readily available treatment option. The exploration of methods to reduce costs and to determine which CAR-T cells are the most effective...

pharmacology & pharmacy
CAR-T cell manufacturing landscape – lessons from the past decade and considerations for early clinical development

Juliana Dias,John Garcia,Giulia Agliardi,Claire Roddie

DOI: https://doi.org/10.1016/j.omtm.2024.101250

2024-04-18

Abstract:CAR-T cell therapies have consolidated their position over the last decade as an effective alternative to conventional chemotherapies for the treatment of a number of haematological malignancies. With an exponential increase in the number of commercial therapies and hundreds of Phase 1 trials exploring CAR-T cell efficacy in different settings (including autoimmunity and solid tumours), demand for manufacturing capabilities in recent years has considerably increased. In this review, we explore the current landscape of CAR-T cell manufacturing and discuss some of the challenges limiting production capacity worldwide. We describe the latest technical developments in GMP production platform design to facilitate the delivery of a range of increasing complex CAR-T cell products, and the challenges associated with translation of new scientific developments into clinical products for patients. We explore all aspects of the manufacture process, namely early development, manufacturing technology, quality control and the requirements for industrial scaling. Finally, we discuss the challenges faced as a small academic team, responsible for the delivery of a high number of innovative products to patients. We describe our experience in the set-up of an effective bench-to-clinic pipeline, with a streamlined workflow, for implementation of a diverse portfolio of Phase 1 trials.

medicine, research & experimental
Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas

Mengyang Di,Kunal C Potnis,Jessica B Long,Iris Isufi,Francine Foss,Stuart Seropian,Cary P Gross,Scott F Huntington

DOI: https://doi.org/10.1093/jncics/pkae059

2024-07-01

Abstract:High upfront cost may be a barrier to adopting chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory B-cell lymphoma. Data on the real-world costs are limited. Using the Blue Cross Blue Shield Axis database, we evaluated 271 commercially insured patients who received CAR-T therapy for B-cell lymphoma (median age = 58 years; men = 68%; diffuse large B-cell lymphoma = 87%; inpatient CAR-T therapy = 85%). Our peri-CAR-T period of interest was from 41 days before to 154 days after CAR-T therapy index divided into seven 28-day intervals. Median total costs were $608 100 (interquartile range, IQR = $534 100-$732 800); 8.5% of patients had total costs exceeding $1 million. The median cost of CAR-T therapy products was $402 500, and the median out-of-pocket copayment was $510. Monthly costs were highest during the month of CAR-T therapy administration (median = $521 500), with median costs below $25 000 in all other 28-day intervals. Costs of CAR-T therapy use were substantial, largely driven by product acquisition. Future studies should examine the relationship between costs, access, and financial outcomes.
Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing

Dimitrios L. Wagner,Ulrike Koehl,Markus Chmielewski,Christoph Scheid,Renata Stripecke

DOI: https://doi.org/10.3389/fimmu.2022.865424

IF: 7.3

2022-06-18

Frontiers in Immunology

Abstract:T cells modified for expression of Chimeric Antigen Receptors (CARs) were the first gene-modified cell products approved for use in cancer immunotherapy. CAR-T cells engineered with gammaretroviral or lentiviral vectors (RVs/LVs) targeting B-cell lymphomas and leukemias have shown excellent clinical efficacy and no malignant transformation due to insertional mutagenesis to date. Large-scale production of RVs/LVs under good-manufacturing practices for CAR-T cell manufacturing has soared in recent years. However, manufacturing of RVs/LVs remains complex and costly, representing a logistical bottleneck for CAR-T cell production. Emerging gene-editing technologies are fostering a new paradigm in synthetic biology for the engineering and production of CAR-T cells. Firstly, the generation of the modular reagents utilized for gene editing with the CRISPR-Cas systems can be scaled-up with high precision under good manufacturing practices, are interchangeable and can be more sustainable in the long-run through the lower material costs. Secondly, gene editing exploits the precise insertion of CARs into defined genomic loci and allows combinatorial gene knock-ins and knock-outs with exciting and dynamic perspectives for T cell engineering to improve their therapeutic efficacy. Thirdly, allogeneic edited CAR-effector cells could eventually become available as "off-the-shelf" products. This review addresses important points to consider regarding the status quo , pending needs and perspectives for the forthright evolution from the viral towards gene editing developments for CAR-T cells.

immunology

CAR-T and cellular gene therapies are too expensive

Technological and Manufacturing Innovation Drive Improved Access to Engineered T Cell Therapies

Challenges in Global Access to CAR-T Cells: an Asian Perspective.

Manufacturing innovation to drive down cell therapy costs

CAR T-Cell Production Using Nonviral Approaches

CAR-T cell therapy in India requires a paradigm shift in training, education and health care processes

Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health

Lentiviral Vectors in CAR-T Cell Manufacturing: Biological Principles, Manufacturing Process, and Frontier Development

Availability and financing of CAR-T cell therapies: A cross-country comparative analysis

Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative

Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?

Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility

A roadmap for affordable genetic medicines

Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma

Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India

Reducing the costs of blockbuster gene and cell therapies in the Global South

Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review

Importance of CAR-T cell therapy monitoring using high-throughput assays

CAR-T cell manufacturing landscape – lessons from the past decade and considerations for early clinical development

Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas

Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing